On Monday, Divi Laboratories consolidated net profit, which has been increased by 78 per cent to Rs 895 crore in the fourth quarter on March 31, 2022. In the last quarter, the drugmaker has reported a net profit of Rs 502 crore, and revenue from operation rose to Rs 2 518 crores, against Rs 1 788 crore in the year-ago period, as per the company’s statement.

• Foreign Inflows Fail to Lift Rupee as RBI Builds Dollar Buffer
• Airbound Raises $37 Million to Scale Autonomous Delivery Network
• Trump Eyes 7.5% Overcapacity Tariff on China Ahead of Xi Visit
• Afcons Infrastructure Shares Jump After Rs 335.5 Crore Arbitration Award
• Aegis Logistics Transfers Ammonia Terminal to Arm for Rs 525 Crore

For the year ended in March 2022, Divi Laboratories Ltd posted a consolidated net profit of Rs 2,960 crore against Rs 1,984 crore in FY21.

Revenue from operations rose to Rs 8,960 crore compared to Rs 6,969 crore in 2020-21.
The company said its board had recommended a dividend of Rs 30 per share of the face value of Rs 2 (1,500 per cent) for 2021-22, subject to members’ approval at the ensuing annual general meeting.

Shares of the company were trading 6.37 per cent down at Rs 4,032.35 apiece on the Bombay Stock Exchange (BSE).